Important Safety Information Contraindications: Active cancer or malignancy (use only with medical supervision) Pregnancy or breastfeeding (insufficient safety data in these populations) Known allergy to peptide compounds Severe uncontrolled medical conditions without physician oversight Monitoring recommendations: While intensive monitoring is not required as with growth hormone, baseline and periodic assessment of body composition, basic metabolic panel, and general health markers ensures optimal results and safety
References FDA Bremelanotide (Vyleesi) prescribing information: dosing, safety, and use limitations NCBI Bookshelf (LiverTox) Bremelanotide: mechanism, clinical use, and hepatic safety profile PMC Bremelanotide for treatment of female hypoactive sexual desire disorder: clinical trial review Mayo Clinic Bremelanotide (subcutaneous route): side effects, dosage, and precautions PubMed Evaluation of Melanotan-II: pilot phase-I clinical study on safety and efficacy RxList Melanotan-II: uses, side effects, dosing, and precautions overview Bachem Handling and storage guidelines for peptides: lyophilized and reconstituted stability NCBI Bookshelf (WHO) Best practices for injections and related procedures: asepsis and technique Healthline Subcutaneous injection: technique, sites, and step-by-step guidance CDC Vaccine administration: subcutaneous injection angle and site selection Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
Goncalves E, Bell DSH
While its generally well tolerated, people with existing liver conditions should only use it under medical supervision
